The QualityStocks Daily Thursday, October 5th, 2023

Today's Top 3 Investment Newsletters

MarketClub Analysis(ORTX) $15.9500 +95.95%

SmallCapRelations(ODYY) $0.1075 +35.35%

Broad Street(ATAI) $1.5200 +16.03%

The QualityStocks Daily Stock List

FSD Pharma Inc. (HUGE)

QualityStocks, Schaeffer's, BUYINS.NET, StockMarketWatch, MarketClub Analysis, Penny Dreamers, InvestorPlace, CFN Media Group, bullseyeoptiontrading and AwesomeStocks reported earlier on FSD Pharma Inc. (HUGE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into a definitive agreement with Celly Nutrition Corp. According to the announcement, the Oct. 4, 2023, agreement outlines the distribution of a portion of FSD Pharma's shareholdings of Celly Nu to certain securityholders of FSD Pharma. The company noted that it has scheduled a virtual meeting on Nov. 20, 2023, for FSD Pharma securityholders to consider and vote on a special resolution approving the agreement, or plan of arrangement. A prerevenue, early-stage research and development company, Celly Nu will focus on developing and manufacturing consumer products in the dietary supplement industry. Closing of the transaction is subject to several conditions, and the final details of the plan of arrangement are subject to change.

“There is no certainty that the transaction will be completed as currently proposed or at all,” the company stated in the press release. “There will be no change in FSD Pharma securityholders’ proportionate ownership in FSD Pharma Securities as a result of the plan of arrangement. In addition, holders of FSD Pharma options and nondistribution warrants as at the effective date of the plan of arrangement will have such FSD options and nondistribution warrants adjusted in accordance with their terms as a result of the transaction.”

To view the full press release, visit

About FSD Pharma Inc.

FSD Pharma Inc. is a biotechnology company with two candidates in different stages of development. Lucid Psychss Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-MS and UNBUZZD(TM). Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle. For more information about the company, please visit

FSD Pharma Inc. (HUGE), closed Thursday's trading session at $1.19, off by 3.252%, on 99,959 volume. The average volume for the last 3 months is 1.284M and the stock's 52-week low/high is $0.6181/$2.10.

Bruush Oral Care Inc. (BRSH)

StockWireNews, StockStreetWire, Small Cap Firm, ProTrader, Fierce Analyst, QualityStocks, Kiplinger Today, InvestorPlace and AwesomeStocks reported earlier on Bruush Oral Care Inc. (BRSH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bruush Oral Care (NASDAQ: BRSH), a company committed to inspiring confidence through brighter smiles and better oral health, has entered into a securities purchase agreement with an institutional investor. The company anticipates the purchase agreement to total an estimated $5 million in gross proceeds before deducting standard fees and other offering expenses. According to the announcement, the company plans to issue 79,724 common shares, a prefunded common share purchase warrant to purchase 7,181,146 common shares, and a common share purchase warrant to purchase 8,350,000 common shares — all as part of the private placement. The company noted that the common warrants and prefunded warrants have a five-year term from the date of issuance, with the closing of the private placement planned on or about Oct. 3, 2023. EF Hutton, division of Benchmark Investments LLC. is acting as the exclusive placement agent for the private placement.

To view the full press release, visit

About Bruush Oral Care Inc.

Bruush Oral Care is on a mission to inspire confidence through brighter smiles and better oral health. Founded in 2018, Brüush is an oral care company that is disrupting the space by reducing the barriers between consumers and access to premium oral care products. The company is an e-commerce business with a product portfolio that currently consists of a sonic-powered electric toothbrush kit and brush head refills. Brüush has developed a product to make upgrading to an electric brush appealing with three core priorities in mind: (i) a high-quality electric toothbrush at a more affordable price than a comparable electric toothbrush from the competition; (ii) a sleek, countertop-friendly design; and (iii) a convenient brush head refill subscription program that eliminates the frustrating experience of purchasing replacement brush heads at the grocery/drug store. The company is rooted in building a brand that creates relevant experiences and content, with the goal of becoming the go-to oral care brand for millennials and Generation Z. For further information about the company, visit

Bruush Oral Care Inc. (BRSH), closed Thursday's trading session at $0.9701, off by 4.8922%, on 45,857 volume. The average volume for the last 3 months is 426,546 and the stock's 52-week low/high is $0.921/$29.9925.

Trulieve Cannabis Corp. (TCNNF)

InvestorPlace, MarketBeat, Wealth Insider Alert, Daily Trade Alert, Top Pros' Top Picks, Cabot Wealth, The Street, QualityStocks, Trades Of The Day, Profit Trends, TradersPro, The Online Investor and StreetInsider reported earlier on Trulieve Cannabis Corp. (TCNNF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A campaign behind a UK-based study to research the effects of marijuana use on the brain is struggling to recruit Black and Asian volunteers who smoke cannabis regularly. The lack of adequate representation in the volunteer pool has raised concerns that the study’s findings would not be truly representative of the United Kingdom’s population.

With £2.5m ($3.04 million) in funding, the King’s College London study seeks to understand how cannabis use can lead to psychosis and paranoia in some users but have no such effects in other users. Findings from the upcoming study could open the door to expanded therapeutic use of cannabis and increase the safety of illicit recreational cannabis use.

But while White people have volunteered for the study in relatively large numbers, few Asian and Black cannabis users have volunteered for the study. After 18 months of working to build a 3,000-strong pool of marijuana users from the London Area, the “Cannabis and Me” campaign still needs to recruit hundreds more Asian, Caribbean and Black people.

Understandably, these two communities have met attempts to collect data about illicit drug use with suspicion and distrust. A 2021 analysis by the Liberal Democrats found that Black people in the UK are around 12 times more likely than White people to be arrested and prosecuted for marijuana possession.

Former police chief and the Liberal Democrat’s House of Lords home affairs spokesperson Brian Paddick said at the time that law enforcement’s focus on marijuana possession was undermining the Black community’s confidence and trust in the police. Asian and Black people also have an 11.8 cannabis possession conviction rate compared to White people, at 2.4 times even though they have lower self-reported rates of cannabis use.

Furthermore, Black people in the UK cumulatively make up a quarter of all cannabis possession convictions even though they make up less than 4% of the country’s population.

The two communities’ unwillingness to participate in the cannabis study points to a deeper issue in research science: Black people and other ethnic minorities have little representation in clinical research. This underrepresentation was especially present in clinical trials for coronavirus vaccines even though the pandemic had a significantly larger impact on minorities such as Asians and Black people.

Marketing consultant and head of the campaign’s recruitment drive William Gadsby-Smith says that for people who have had their trust in the government and law enforcement eroded by years of corrupt and racist police, saying no to participating in such initiatives is extremely easy.

An advocacy group based in Brixton that tackles racism in the UK’s legal system called Unjust refused to help the campaign recruit participants from minority groups. According to Unjust’s founding director Katrina French, the study’s findings on cannabis and psychosis could potentially lead lawmakers to expand cannabis criminalization among Black males while ignoring the effects of cannabis prohibition.

The fact that licensed companies such as Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) are permitted to operate in certain jurisdictions in the world doesn’t mean that all forms of prohibitionist policies were rolled back. The struggle for an end to prohibition is an ongoing process, and the reluctance of Blacks to enroll for the study above is testament that more still needs to be done.

Trulieve Cannabis Corp. (TCNNF), closed Thursday's trading session at $5.01, off by 6.8773%, on 529,961 volume. The average volume for the last 3 months is 1.93M and the stock's 52-week low/high is $3.42/$16.11.

Cenntro Electric Group Ltd. (CENN)

QualityStocks, GreenCarStocks, TradersPro, Penny Stock and InvestorPlace reported earlier on Cenntro Electric Group Ltd. (CENN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

After nearly a decade of dominating the electric vehicle industry, Western automakers are pushing back against Tesla’s dominance in the high-end EV segment. Patryk Doornebos from Car Triple notes that although Tesla is still a go-to option for drivers interested in high-end electric cars, the segment has seen the introduction of pricey EV models from companies such as Lucid and Porsche, which are giving Tesla a run for its money.

The Tesla Model S was crowned the best-selling luxury sedan in the United States in 2016 and has enjoyed plenty of demand from affluent consumers since. Tesla began deliveries of the Model S Plaid in mid-2021 at a starting price of $89,990. The Tesla Model S Plaid can accelerate from 0 to 60 miles per hour in just under two seconds and boasts a top speed of 200 miles per hour.

Its luxurious yet minimalist interior design coupled with futuristic engineering, a powerful engine and industry-leading autopilot technology make the Model S Plaid an attractive purchase for affluent drivers.

The Mercedes-Benz EQS takes luxury to another level with a top-notch HEPA filtration system that keeps the interior environment pristine, a 56-inch curved hyperscreen along the entire dashboard, and a futuristic infotainment and control system. With a starting price of $104,400, the Mercedes-Benz EQS has a 478-mile range, a top speed of 130 miles per hour, and can accelerate from 0 to 60 miles per hour in 5.5 seconds.

Lucid Air is Lucid Motors’ entry into the luxury electric vehicle segment. It has a starting price of $89,050, and the entry-level models come equipped with a single electric motor capable of generating up to 1,111 horsepower and a 112 kWh battery pack with fast-charging capabilities. The Lucid Air has a range of 520 miles on a single charge and features a spacious interior cabin with a next-generation, 34-inch 5k display that floats over the dashboard.

The Rivian R1T is Rivian’s attempt to break into America’s massive market for pickup trucks. It is a high-end, fully electric pickup truck with a $73,000 starting price, as much as 835 horsepower, and up to 352 miles on a single charge. Unlike other luxury EVs, the Rivian R1T grants affluent drivers the opportunity to enjoy off road adventures in their electric cars. Although it isn’t equipped with Android Auto or Apple CarPlay, the R1T’s off-road capabilities more than make up for this deficiency.

The Porsche Taycan is a fully electric luxury sports car with a starting price of $90,900. It combines Porsche’s classic aesthetic with powerful acceleration and a range of up to 246 miles on a single charge. The premium Tycan Turbo S Class Turismo has a $187,500 starting price and can accelerate from 0 to 60 miles per hour in only 2.7 seconds.

While many companies jostle to grab market share in the luxury EV segment, many other startups such as Cenntro Electric Group Ltd. (NASDAQ: CENN) are looking to dominate the commercial electric vehicle market, which could be more lucrative as there is currently no race to the bottom in terms of price.

Cenntro Electric Group Ltd. (CENN), closed Thursday's trading session at $0.2269, off by 3.4057%, on 1,869,981 volume. The average volume for the last 3 months is 10.168M and the stock's 52-week low/high is $0.2191/$1.20.

Freeport-McMoRan Inc. (FCX)

MarketClub Analysis, The Street, InvestorPlace, Schaeffer's, Kiplinger Today, SmarTrend Newsletters, StocksEarning, MarketBeat, Barchart, StreetAuthority Daily, Trades Of The Day, StreetInsider, Investopedia, Money Morning, TopStockAnalysts, Daily Trade Alert, QualityStocks, Zacks, Louis Navellier, VectorVest, Trading Markets,, ProfitableTrading, The Growth Stock Wire, Daily Wealth, The Wealth Report, Top Pros' Top Picks, Trading Tips, The Online Investor, TheStockAdvisors, StreetAlerts, Wall Street Elite, All about trends, Streetwise Reports, TradingMarkets, Leeb's Market Forecast, StockEarnings, Market FN, DividendStocks, Early Bird, Dividend Opportunities, Investors Alley, TheStockAdvisor, Market Report, StockTwits, InvestmentHouse, Investor Guide, Investment House, Wealth Insider Alert, Trading Concepts, INO Market Report, InvestorGuide, Cabot Wealth, Money and Markets, Options Trader Elite, The Best Newsletters, Market Intelligence Center Alert, Energy and Capital, The Motley Fool, Darwin Investing Network, Bourbon and Bayonets, Trade of the Week, AnotherWinningTrade, Wealth Daily, Investing Signal, Wyatt Investment Research, Buttonwood Research, MarketWatch, Market Authority, Investor Update, Super Stock Investor, Wealthpire Inc., Wall Street Daily, TradingAuthority Daily, Stock Research Newsletter, Profit Confidential, Street Insider, WStreet Market Commentary, Weekly Wizards, Uncommon Wisdom, TradersPro, AllPennyStocks, InvestorsUnderground, CNBC Breaking News, Daily Markets, MiningNewsWire, 24/7 Trader, Dynamic Wealth Report, Normandy Investment Research, Rick Saddler, FeedBlitz, FNNO Newsletters, Profits Run, The Tycoon Report, Investing Daily, Investment U, Weekly Market Strategies, Inside Investing Daily, Insider Wealth Alert, SmallCapVoice, Oakshire Financial, Investiv, StreetAuthority Investor Update, Navellier Growth, Pennybuster, Money Wealth Matters, Greenbackers, BUYINS.NET, ChartAdvisor, Stock Barometer, Inside Trading, Market Intelligence Center, Daily Profit, Stockhouse, Hit and Run Candle Sticks, Forbes, Average Joe Options, StockLockandLoad, TradingPub,, Trader Prep, The Street Report, The Stock Dork, The Night Owl, The Daily Market Alert, Terry's Tips, Taipan Daily, Super Stock Picker, StreetAuthority Financial, Stocks To Watch, Penny Sleuth, StockMarketWatch, InsiderTrades, Stock Beast, SmallCap Network, Shah's Insights & Indictments, Schaeffer’s, PowerRatings Stocks, Penny Stock Buzz, Milestone Capital Growth Portfolio, MicroCap Gems, MarketTamer, Jason Bond, Investors Underground, Investors Daily Edge, InvestorIntel and StockRockandRoll reported earlier on Freeport-McMoRan Inc. (FCX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Dubai is heralded as the best destination to buy gold by individuals from various parts of the world based on its reputation for quality and transparent gold-pricing system. The gold markets in the city have something to offer any and all, from those seeking to admire the craftsmanship and those who want to invest in gold to those who are looking to purchase fine jewelry.

Other factors that attract gold buyers to Dubai include:

Minimal taxes

Unlike other countries around the world, Dubai imposes minimal import duties and taxes on gold, making it a cost-effective place to purchase the yellow metal. This, in turn, reduces premiums for buyers.

Spot pricing

The price of gold in Dubai is linked to global spot prices. This means that those wishing to purchase the yellow metal in the city can expect prices that reflect the global market rate, which make Dubai a fair and competitive market.

Competitiveness of the market

The city’s gold market is very competitive, given the high number of jewelers and dealers who take part in the market. This competition benefits customers because it allows them to compare quality and prices across an extensive range of options.

Quality assurance

The city’s gold market adheres to strict quality standards, affording buyers high-quality, genuine gold jewelry. The Dubai Gold and Jewelry Group is tasked with ensuring that all members adhere to the stringent guidelines on quality.

Investment opportunities

The Dubai Gold and Commodities Exchange is focused on providing a platform to trade gold, while also offering avenues to diversify investments in the gold market.

Low making charges

In comparison to most countries, making charges for gold jewelry in Dubai are lower. This attracts residents as well as tourists, encouraging them to purchase exquisite and unique pieces of jewelry.

Secure and safe transactions

Dubai has a reputation for resident dealers and jewelry stores that follow ethical business practices, which affords consumers’ confidence on their purchases.

Choice and variety

The city has an extensive array of gold jewelry designs from contemporary trends to traditional Arabic styles, leaving shoppers spoilt for choice on pieces that may suit their personal preferences.


Most businesses provide customization services, which enables consumers to design personalized pieces that fit their individual specifications and preferences.

Tourist friendly

Dubai is a popular tourist destination globally, with most businesses employing multilingual staff. This allows tourists, especially foreigners who don’t speak English or Arabic, to fully take advantage of its tax-free shopping policies.

It is highly probable that major gold extraction companies such as Freeport-McMoRan Inc. (NYSE: FCX) have a sizeable clientele in Dubai given how prominent the city is in terms of the amount of gold that is traded there each year.

Freeport-McMoRan Inc. (FCX), closed Thursday's trading session at $35.37, off by 1.3664%, on 13,218,395 volume. The average volume for the last 3 months is 471,210 and the stock's 52-week low/high is $27.50/$46.73.

Compass Pathways PLC (CMPS)

InvestorBrandNetwork, QualityStocks, InvestorPlace, MarketBeat, Daily Trade Alert, StreetInsider, Schaeffer's, Trades Of The Day and The Street reported earlier on Compass Pathways PLC (CMPS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recent psychedelic study has left researchers concerned that chronic psychedelic microdosing could cause valvular heart disease. Psychedelics have exploded in popularity in recent years thanks to numerous claims of their medical efficacy, leading to an increase in psychedelic microdosing among the American population.

Microdosing is the practice of taking very small doses of a psychedelic to gain some of its purported benefits, such as heightened creativity, better mental well-being and increased productivity, without experiencing any mind-bending effects.

With a growing number of studies connecting various psychedelics to significant improvements against mental conditions such as depression, anxiety, eating disorders and post-traumatic stress disorder (PTSD), psychedelics present an attractive alternative to conventional mental health treatments.

However, findings from a recent scientific review show that long-term psychedelic microdosing may have adverse health effects, especially in regard to heart health. Published in the “Journal of Psychopharmacology,” the review noted that chronic psychedelic microdosing may increase the risk of developing valvular heart disease (VHD), a condition that affects heart valves, which regulate blood flow in the heart. VHD can range from mild to serious and cause symptoms such as shortness of breath, chest pains, fatigue and, in extreme cases, heart failure.

The researchers found that microdosed psychedelics such as psilocybin, LSD and mescaline may influence the risk of VHD by interacting with 5-HT2B receptors that are associated with serotonin neurotransmitters and are involved in regulating a variety of physiological processes across the body. After studying LSD, DMT, psilocin and MDMA, the research team found that psilocin had a higher risk of VHD than LSD because it could bind more tightly to 5-HT2B receptors compared to 5-HT2A.

DMT also presented a risk of influencing VHD development, but its very short half-life increased its safety margins compared to other psychedelics.

Mescaline, on the other hand, has a low potency, which made it harder for researchers to draw conclusions on how it interacted with 5-HT2B receptors. Still, the researchers surmised that the psychedelic presented a potential risk for VHD based on its binding affinity and concentrations within the blood plasma. MDMA exhibited the highest risk of developing VHD. Both MDMA and MDA, its metabolite, have minimal safety margins when microdosed because they are strong 5-HT2B antagonists.

Additionally, the existence of VHD cases in long-term MDMA users adds to the evidence that the psychedelic has a strong association with valvular heart disease.

The research team concluded that chronic psychedelic microdosing may be associated with the development of VHD and called for further studies to better understand the risk of long-term psychedelic microdosing.

The concerns raised by this research focused on the possible link between chronic psychedelic microdosing and VHD lends credence to the position held by startups such as Compass Pathways PLC (NASDAQ: CMPS) that psychedelics should only be used under medical supervision; their drug-development pipelines are based on this premise.

Compass Pathways PLC (CMPS), closed Thursday's trading session at $6.85, up 3.3183%, on 666,127 volume. The average volume for the last 3 months is 20.127M and the stock's 52-week low/high is $6.42/$11.91.

Aurora Cannabis Inc. (ACB)

InvestorPlace, Schaeffer's, MarketBeat, MarketClub Analysis, StocksEarning, The Street, Trades Of The Day, Daily Trade Alert, StockEarnings, StreetInsider, The Online Investor, Wealth Insider Alert, Market Intelligence Center Alert, QualityStocks, Kiplinger Today, StockMarketWatch, CFN Media Group, Investopedia, Stock Up Featured, Profit Trends, BUYINS.NET, BlackSwanAlert, StreetAuthority Daily, The Rich Investor, Jim Cramer, Early Bird, Investors Alley, Cannabis Financial Network News, Wall Street Window, CNBC Breaking News, Daily Profit, Tradespoon, Inside Trading, Outsider Club, TheTradingReport, Zacks, The Wealth Report, Market Intelligence Center, Technology Profits Daily, Money and Markets and Top Pros' Top Picks reported earlier on Aurora Cannabis Inc. (ACB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Wholesale marijuana prices have recently found stability or even experienced slight rebounds in select markets during the summer. However, industry experts are advising cultivators to prepare for a potential renewed downward trend as the fall harvest bolsters inventories through the year’s end.

Ben Burstein, a strategist at LeafLink, points out that a significant inventory buildup is observed across the industry during this time of the year, particularly around the harvest season, triggering substantial price drops. LeafLink’s data gathered from 13 states shows that after several months of consistently hitting record-breaking lows, wholesale cannabis flower prices have stabilized in certain well-established markets, such as Michigan and California. While this is good news for producers, retailers are grappling with rising costs.

In California, for instance, retailers paid more than 29% more for marijuana flower in August compared to the previous year due to a 15% decline in licensed square footage. Meanwhile, Michigan witnessed a 19% price rebound since the end of 2022, registering more than a 4% increase compared to the previous year.

In contrast, Oregon and Oklahoma, known for having some of the lowest wholesale marijuana prices in the country, experienced price increases of more than 5% and 7%, respectively, compared to the previous year. On a broader scale, prices across the 13 states exhibited a 4% year-over-year increase in August 2023 and a 15% rise compared to the end of last year.

Despite these positive trends, wholesalers in most states continue to grapple with price compression due to an oversupply of inventory. According to Cannabis Benchmarks, prices have reached a “historic low,” with the spot index plummeting to only $935 per pound, a 7.3% decline from September last year.

Burstein noted that the marijuana market tends to follow a similar pattern in most states. When medical cannabis programs launch, prices per pound can reach as high as $10,000. However, as more growers become licensed, prices gradually decline.

For instance, in Maryland, where recreational cannabis sales commenced in July, prices surged by more than 40% from August 2022 to August 2023. In Missouri, adult-use sales introduced in February increased wholesale cannabis flower prices from around $1,500 per pound in late 2022 to more than $2,000 per pound in August.

Arizona, after experiencing oversupply issues in 2021 and 2022 due to extensive greenhouse cultivation, saw prices inch up slightly in August, rising by more than 2%. Colorado, on the other hand, currently boasts the lowest wholesale prices in the nation, standing at $810 per pound in August.

In Massachusetts, the market is adjusting to reduced out-of-state demand, dropping from 25% to 15% following cannabis legalization in neighboring states such as Vermont, New York and Connecticut. Wholesale prices in the state have fallen by more than 27% since August 2022. Looking ahead, Burstein predicts further declines in the latter half of the year, as pricing shifts typically occur between the harvest and the early months of spring, when product availability decreases.

Cannabis companies such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) are used to these seasonal changes in the wholesale price of marijuana, and likely calculate this into their pricing policies so that they still earn a profit by the end of the year.

Aurora Cannabis Inc. (ACB), closed Thursday's trading session at $0.5674, up 2.604%, on 6,164,143 volume. The average volume for the last 3 months is 39,608 and the stock's 52-week low/high is $0.434/$1.62.

Vext Science (VEXTF)

MarketBeat reported earlier on Vext Science (VEXTF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Vext Science Inc. (OTCQX: VEXTF) (CNSX: VEXT) (FRA: VV5) is an integrated agricultural technology, services and property management firm operating in the cannabis industry in the United States.

The firm has its headquarters in Phoenix, Arizona and was incorporated in 2015, on December 11th by Jason Thai Nguyen. Prior to its name change in November 2019, the firm was known as Vapen MJ Ventures Corp. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm serves consumers around the globe, with a focus on those in the U.S.

The enterprise manufactures THC cartridges, concentrates, edibles and accessories under the Vapen brand, and hemp-based products under the Pure Touch Botanicals brand as well as the Vapen CBD and Herbal Wellness brands. It has THC concentrates, edibles, and distillate cartridge brands sold in various states’ dispensaries. It owns and operates cultivation facilities, fully built-out manufacturing facilities as well as dispensaries in both Arizona and Ohio. Additionally, it offers management, advisory, cultivation, and dispensary services to entities in the cannabis field through joint operations agreements. Furthermore, the enterprise is also engaged in selling CBD products and branded merchandise. Vapen Brands’ products are the wholesale products sold in its dispensaries as well as others. The Vapen Brand is an edible and concentrate brand.

The company recently signed an agreement to acquire a pair of additional Ohio retail locations, a move that will greatly extend its consumer reach while also opening the company up to new growth and investment opportunities that could generate value for its shareholders.

Vext Science (VEXTF), closed Thursday's trading session at $0.2112, off by 1.5614%, on 3,190 volume. The average volume for the last 3 months is 6,831 and the stock's 52-week low/high is $0.14475/$0.27.

Just Eat (TKAYF)

We reported earlier on Just Eat (TKAYF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Just Eat N.V. (OTC: TKAYF) (OTC: JTKWY) (AMS: TKWY) (LON: JET) (ETR: T5W) is an online food delivery marketplace that provides mobile applications for ordering and delivering food and beverages.

The firm has its headquarters in Amsterdam, the Netherlands and was incorporated in 2000 by Laurens Groenendijk and Jitse Groen. It operates as part of the internet retail industry, under the consumer cyclical sector. The firm serves consumers around the globe.

The company operates through the North America; Northern Europe; United Kingdom and Ireland; and Southern Europe, and Australia and New Zealand geographical segments. The North America segment includes the United States and Canada. The Northern Europe segment consists of Austria, Belgium, Denmark, Germany, Luxembourg, Norway, Poland, Switzerland, Slovakia, and the Netherlands. The Southern Europe and ANZ segment refers to Australia, Bulgaria, France, Israel, Italy, New Zealand, Portugal, Romania, and Spain.

The enterprise focuses on connecting consumers and restaurants through its platforms and allowing users to order food from nearby restaurants and have the food delivered to their homes. It transmits the order placed by customers and forwards it to restaurants, which prepare and deliver the meal. It operates the websites,,,,,,,,,, and, among others. The platforms feature various kinds of restaurants.

The company remains committed to better meeting the evolving demands of its consumers and generating additional value for its stakeholders.

Just Eat (TKAYF), closed Thursday's trading session at $14.23, even for the day. The average volume for the last 3 months is 2,119 and the stock's 52-week low/high is $11.955/$26.50.

Fandifi Technology (FDMSF), QualityStocks, NetworkNewsWire, StocksToBuyNow, Small Cap Firm, SeriousTraders, Winston Small Cap, StockBlogs and Tiny Gems reported earlier on Fandifi Technology (FDMSF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Fandifi Technology Corp (OTC: FDMSF) (CNSX: FDM) (FRA: TQ4) is a company focused on developing and monetizing prediction and wagering Esports entertainment platforms for engaging fans on mobile apps.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2006, on May 12th by Blair Lawrence Naughty and Tristan Brett. Prior to its name change in March 2022, the firm was known as Fandom Sports Media Corp. It operates as part of the software-application industry, under the technology sector. The firm serves consumers across the globe.

The company operates through the Canada, Curacao and Cyprus geographical segments. Its platform enables content creators to enhance gamification of their content and enable fan engagement with their communities.

The enterprise’s primary business is the development and monetization of all ages prediction and wagering Esports Entertainment Platform for engaging fans on mobile applications. It offers a platform for content creators to increase fan engagement and create new streams. Their platform, called Fandifi, uses a neural network for predictions in events such as esports, sports, live-streamed broadcasts, and more. The Fandifi platform allows content creators to increase the gamification of their content and engage their communities regardless of the form of distribution. The platform’s product is a prediction engine, which facilitates real-time predictions in various events, helping content creators to extend peak viewership metrics.

The firm recently entered a 2-year commercial agreement with Dziki Warszawa for the upcoming 2023/24 and 2024/25 seasons of the Polska Liga Koszykowki. This may open the firm up to new growth and investment opportunities while also bringing in additional revenues into the firm.

Fandifi Technology (FDMSF), closed Thursday's trading session at $0.009, even for the day. The average volume for the last 3 months is 535 and the stock's 52-week low/high is $0.0087/$0.08.

Concrete Leveling Systems (CLEV)

We reported earlier on Concrete Leveling Systems (CLEV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Concrete Leveling Systems Inc. (OTC: CLEV) is a company focused on manufacturing and selling specialized equipment for use in the concrete leveling industry.

The firm has its headquarters in Canton, Ohio and was incorporated in 2007, on August 28th by Suzanne I. Barth. It operates as part of the farm and heavy construction machinery industry, under the industrials sector. The firm serves consumers in the United States.

The company operates through 2 divisions; the Concrete leveling division and the Gaming and hospitality division. The Concrete leveling division fabricates and markets a concrete leveling service unit utilized in the concrete leveling industry. This unit comprises of a mixing device to mix lime with water and a pumping device capable of pumping the mixture under pressure into pre-drilled holes. On the other hand, the gaming and hospitality division of the business focuses on casino gaming, hospitality, entertainment, and leisure time industries, and will pursue opportunities in the tribal and commercial casino gaming industries, both in California and Nevada.

The enterprise also provides mud and slab jacking products for leveling sidewalks, driveways, patios, steps, streets, floors, curbs, gutters, and swimming pool decks.

The firm, which recently provided an update on its operations, remains committed to bringing in additional investments into the firm via partnerships and generating value for its shareholders.

Concrete Leveling Systems (CLEV), closed Thursday's trading session at $1.2, even for the day. The average volume for the last 3 months is 398,821 and the stock's 52-week low/high is $0.8671/$3.59.

Unrivaled Brands (UNRV)

We reported earlier on Unrivaled Brands (UNRV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Unrivaled Brands Inc. (OTCQB: UNRV) is a vertically integrated cannabis multi-state operator that is focused on cultivating, producing, distributing and retailing medical and adult-use cannabis products in Oregon, California and Nevada.

The firm has its headquarters in Santa Ana, California and was incorporated in 2008 on July 22nd. Prior to its name change in July 2021, the firm was known as Terra Tech Corp. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm serves consumers globally.

The company operates through the Cannabis Cultivation and Distribution and Cannabis Retail segments. The Cannabis Cultivation and Distribution segment includes cannabis cultivation, production, and distribution operations. On the other hand, the Cannabis Retail segment includes cannabis-focused retail, both physical stores and non-store front delivery.

The enterprise’s offerings include Korova, a brand of high potency products across multiple product categories. It also operates medical marijuana retail and adult use dispensaries and cultivation and production facilities in California, either independently or in conjunction with third parties. The enterprise operates 4 cannabis dispensaries in California: People's in Santa Ana, The Spot in Santa Ana, Blum in Oakland, and Blum in San Leandro.

The firm recently announced executive appointments to begin rebuilding its legacy Korova brand, with its CEO noting that the relaunch would speak to its consumer base that sought maximum potency products. This may help to better meet consumer needs and encourage more investments into the firm.

Unrivaled Brands (UNRV), closed Thursday's trading session at $0.0211, off by 0.471698%, on 79,405 volume. The average volume for the last 3 months is 1.071M and the stock's 52-week low/high is $0.012/$0.055.

The QualityStocks Company Corner

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

FingerMotion (NASDAQ: FNGR), a mobile services and data company, today announced its retention of attorney Mark R. Basile and his securities litigation firm, The Basile Law Firm P.C., to investigate recent activities surrounding the company's stock performance and to take whatever legal action necessary to prevent potential market participants utilizing unlawful means from further hurting FingerMotion shareholders, including the recently published research paper by Capybara Research. "We are pleased to welcome Mr. Basile to our legal team," said Martin Shen, CEO of FingerMotion. "Mr. Basile and his firm understands how dilution funding and certain market participant activities negatively affect retail shareholders and will be leading this investigation and any appropriate actions we may pursue."

To view the full press release, visit

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Thursday's trading session at $5.75, up 5.6985%, on 2,679,180 volume. The average volume for the last 3 months is 4.055M and the stock's 52-week low/high is $1.01/$9.795.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope, Inc. [Nasdaq: KSCP] ("Knightscope" or the "Company"), a leading developer of autonomous security robots and blue light emergency communication systems, today announces three new contracts totaling 5 devices for a New York college, a city in Nevada, and a park in Oklahoma. The goal of a strong emergency communications system is to provide a platform for individuals to reduce the number of possibilities for criminals to commit a crime. A University of Southern California study found that public venues with visible security equipment like blue light emergency towers and phones increased the area's perceived safety, making people feel more comfortable at such locations/venues. The objective is straightforward: when someone identifies their own personal vulnerability to crime, they can mitigate the risk by taking preventative measures and communicating with authorities.

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Thursday's trading session at $0.766, up 1.6724%, on 640,921 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $9.795/$.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

The fluxonium qubits that D-Wave has designed, manufactured, and operated demonstrate properties comparable to the best in scientific literature to date

D-Wave has manufactured and tested fluxonium qubits in a two-dimensional circuit geometry, measuring several factors

D-Wave owns one of the industry's largest quantum computer intellectual property portfolios, with more than 210 issued U.S. patents, and has published more than 100 peer-reviewed papers in leading scientific journals

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world's first commercial supplier of quantum computers, recently announced notable progress in its development of high-coherence qubits, with results expected to have a significant impact on its future quantum technologies. The fluxonium qubits that D-Wave has designed, manufactured, and operated demonstrate quantum properties comparable to the best in scientific literature to date.

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer


With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service


D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Thursday's trading session at $0.9072, up 6.1053%, on 597,149 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3962/$8.29.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, was awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke ("NINDS"), a division of the National Institutes of Health ("NIH"). The grant is to support an Expanded Access Protocol ("EAP") for the company's investigational drug, CNM-Au8(R), in amyotrophic lateral sclerosis ("ALS"). Also referred to as Compassionate Use, an EAP is an FDA-regulated pathway that allows people with a serious and life-threatening disease to access an investigational drug that is not yet approved by the U.S. Food and Drug Administration ("FDA"). "This EAP study will give ALS patients who don't meet the criteria to enroll in a clinical trial an opportunity to try CNM-Au8 as a novel investigational therapy through this EAP program," said Jinsy A. Andrews, M.D., MSc, FAAN, an associate professor of neurology in the Division of Neuromuscular Medicine and director of Neuromuscular Clinical Trials at Columbia University Vagelos College of Physicians and Surgeons. "Programs like this help to advance research and much-needed innovation in ALS."

To view the full press release, visit

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.


CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Thursday's trading session at $0.5434, up 9.9777%, on 2,745,449 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.414/$1.99.

Recent News

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) today provided a technical update on its RapidSX(TM) Demonstration Plant ("Demo Plant") for the separation of heavy and light rare earth elements ("REEs"). Located within Ucore's 5,000 square foot RapidSX(TM) Commercialization and Demonstration Facility ("CDF") in Kingston, Ontario, the Demo Plant is operated by commercialization partner, Kingston Process Metallurgy Inc. ("KPM"). "Over the first two years in Kingston, we proved the technical superiority of our now patent-pending RapidSX(TM) technology platform to mix and separate the chemistry of solvent extraction," said Mike Schrider, Ucore vice president and chief operating officer. "We have since taken those optimization and fine-tuning efforts and engaged in a robust engineering, construction, commissioning, testing and demonstration effort to truly optimize the chemistry delivery and feedback systems to and from the RapidSX(TM) platform within the Demo Plant and across all of the related systems within the CDF. This arduous yet thorough process will soon enable us to discreetly quantify the previous qualitative attributes of the RapidSX(TM) technology platform and the resulting rare earth element products as we incorporate every facet of our engineering and production learning curve from our project execution in Kingston into our underway LA-SMC commercial and technical activities."

To view the full press release, visit

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) is a critical metals (“CM”) separation technology company executing an ESG-centered plan toward establishing a comprehensive North American critical metals supply chain. The company has developed a transformative commercial-ready technology, RapidSX™, for separating and purifying critical metals. Ucore intends to deploy this technology in pursuit of a CM supply chain independent of China for Western original equipment manufacturers (“OEMs”), most notably in the automotive and renewable energy industries.

Ucore’s vision is to become a leading advanced technology company providing best-in-class metal separation products and services to the mining and mineral extraction industry. Its initial focus is on processing heavy and light rare earth elements (“REEs”), disrupting a supply chain that is dominated by China.

China currently controls about 80% of the world’s access to REE mining projects and over 90% of the world’s REE processing capabilities, and it produces about 95% of the goods containing REE components.


Ucore is working to scale Western supply needs by establishing REE separation and rare earth oxide (“REO”) production capabilities in cooperation with strategic upstream supply and downstream offtake partnerships. The company, along with its industry partners, aims to unlock access to Western REEs for current consumer, energy, manufacturing and military sectors.

By 2025, Ucore expects to commercially separate U.S.-friendly sources of REEs and supply OEMs with REOs required to produce rare earth permanent magnets (“REPMs”) – the essential component of electric motors and generators required to support the world’s transition to electrification and sustainable energy sources.

The company intends to contribute to this initiative through the near-term development of a heavy and light rare-earth processing facility in Louisiana and subsequent development of Strategic Metals Complexes (SMCs) in Alaska and Canada, as well as through the longer-term development of its 100%-owned Heavy Rare Earth Element (HREE) mineral resource property at Bokan Mountain on Prince of Wales Island, Alaska.

Ucore is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Demonstration Plant

The Kingston, Ontario, RapidSX™ Demonstration Plant commissioning process is underway. Once commissioned, the plant is designed to demonstrate the commercial capabilities of the RapidSX technology platform.

The RapidSX demo plant will show:

  • The techno-economic advantages of the RapidSX technology platform
  • The processing of tens of tons of heavy and light mixed rare earth element concentrates in a simulated production environment
  • The platform’s ability to operate for thousands of semi-continuous run-time hours
  • Production of high-purity NdPr, praseodymium, neodymium, terbium and dysprosium rare earth elements for early OEM product qualification trials

The demo plant is located within Ucore’s 5,000-square-foot RapidSX Commercialization and Demonstration Facility and is run by its laboratory partner, Kingston Process Metallurgy Inc. (“KPM”).

RapidSX™ Technology

Innovation Metals Corp., acquired by the company in 2020, developed the RapidSX separation technology platform with early-stage assistance from the United States Department of Defense, later resulting in the production of commercial-grade, separated rare earth elements at pilot scale.

RapidSX combines the time-proven chemistry of conventional solvent extraction (SX) with a new column-based platform that significantly reduces time to completion and plant footprint, as well as potentially lowering capital and operating costs. SX is the international REE industry’s standard commercial separation technology and is currently used by all REE producers worldwide for bulk commercial separation of both heavy and light REEs.

Utilizing similar chemistry to conventional SX, RapidSX is not a “new” technology, but it represents a significant improvement on the well-established, well-understood, proven conventional SX separation technology preferred by REE producers.

Strategic Metals Complex

Ucore, engineering partner Mech-Chem Associates Inc. and KPM are developing the full-scale engineering for the company’s first Strategic Metals Complex (SMC). The SMC is a planned REE separation and rare earth oxide production plant slated to commence construction in Louisiana in 2023. It is scheduled to initially process 2,000 tons of total rare earth oxides by the end of 2024, increasing to 5,000 tons in 2026.

The company has three initial U.S.-friendly feedstock agreements in place for the Louisiana complex, along with multiple developing offtake agreements. It received a C$16 million+ incentive package offer from Louisiana Economic Development to support construction of the SMC.

Bokan-Dotson Ridge REE Deposit

Ucore has invested over C$35 million to establish and validate the Bokan-Dotson Ridge resource in preparation for mine design and permitting. Initial drilling is complete, and a Preliminary Economic Assessment has been issued. Next steps for the project include a feasibility study, detailed mine design and permit acquisition. The project can be “near shovel ready” for construction in less than 30 months after receipt of the next stage of development funding.

Market Opportunity

According to a report by Grand View Research, the global rare earth elements market was valued at $2.8 billion in 2018 and is forecast to reach a value of $5.6 billion by 2025, achieving a CAGR of 10.4% during the period. Market growth is driven by increasing demand for these elements in the manufacturing of magnets and catalysts for the automotive industry. Rising demand for electric vehicles to reduce CO2 emissions is expected to propel the use of permanent magnets in the production of EV batteries.

China is the major producer and consumer of REEs. To maintain self-sufficiency and to meet future demand, China has been raising the export tariffs on rare earth elements shipped to various countries, including the U.S., Japan, India, Brazil and the European Union. This led to the current supply-demand gap in these countries, as they rely on imports from China.

China reduced the exports of REEs by 72% in the second half of 2010 to preserve its reserves of these elements and continues to export REEs at reduced levels, thereby affecting industries such as automotive, oil and gas, and electronics, which require an ample amount of rare earth elements.

Management Team

Pat Ryan, P.Eng., is Chairman and CEO of Ucore Rare Metals. He began as a director with the company when he developed a heightened interest in critical metals. Before joining Ucore, he founded and led a multimillion-dollar automotive OEM design and lean manufacturing company. His understanding of complex supply chains across international markets has led to a prime positioning as the global auto industry transitions to vehicle electrification. He holds a Bachelor of Engineering degree from Dalhousie University.

Peter Manuel is Vice President and CFO of Ucore. Prior to joining the company, he practiced as a Chartered Accountant for more than 17 years, providing consulting services to companies in a range of industries, with a focus on the financial services and resource sectors. He spent 10 years in England and Ireland providing assurance, strategic planning, corporate finance and other consulting services to a portfolio of both public and private entities. He holds a Bachelor of Commerce Degree from Dalhousie University.

Michael Schrider, MEng, P.E., is Vice President and COO of Ucore. He is a multidisciplinary engineer who has been involved in manufacturing, engineering and managing complex structural and mechanical systems projects since 1989. He was the Founder, President and Chief Engineer of Schrider & Associates and Alton Bay Design, both engineering services firms. He holds a bachelor’s degree in naval architecture and marine engineering from the University of New Orleans and a master’s degree in mining, geological and geophysical engineering from the University of Arizona.

Mark MacDonald is Vice President of Investor Relations at Ucore. He has over 25 years of experience implementing award winning business development and marketing programs at regional and national levels. As Vice President of Sales, he was responsible for Mediapro Communication’s growth as AT&T Canada’s leading B2B sales partner. He subsequently became Atlantic Regional Vice President of AT&T Canada Corp. He holds a Bachelor of Commerce degree from Dalhousie University.

Ucore Rare Metals Inc. (UURAF), closed Thursday's trading session at $0.5093, up 0.851485%, on 29,885 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.48/$1.15.

Recent News

Electronic Servitor Publication Network Inc. (OTCQB: XESP)

The QualityStocks Daily Newsletter would like to spotlight Electronic Servitor Publication Network Inc. (OTCQB: XESP).

Electronic Servitor Publication Network (OTC: XESP) is a digital engagement company offering a Managed Service that provides unique digital activation and engagement solutions to businesses that seek to optimize growth. The company is making a difference in the global customer engagement solutions market. "The company's Managed Service is powered by a proven, proprietary technology – the Digital Engagement Engine(TM) – which provides intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, which creates digital experiences that accelerate an audience from awareness to action and drive growth. Electronic Servitor Publication Network's Digital Engagement Engine(TM) was designed to drive growth for established and developing organizations and to ensure that client content is relevant, reaches target audiences, and connects with the intended person at the right time. The company calls this ‘Growth as a Service,'" a recent article reads. "Implementing the Digital Engagement Engine(TM) is effortless and completely managed by the Electronic Servitor Publication Network team. This lets customers focus on their brand, product offering and content creation. Using a risk-averse business model, the company provides an easily budgeted quarterly investment and an upside bonus that allows business growth to fund the customer's investment."

To view the full article, visit

Electronic Servitor Publication Network Inc. (OTCQB: XESP) is a digital engagement company offering a managed service which provides digital activation and engagement solutions to companies that seek to optimize their growth. Its managed service is powered by a proven, proprietary technology – the Digital Engagement Engine™. This technology provides intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, which creates digital experiences that accelerate an audience from awareness to action – driving growth.

Electronic Servitor Publication Network’s services are designed to drive growth for both established and developing organizations. Through the optimization of digital interactions within current and new communities, the Digital Engagement Engine™ ensures that client content is relevant, reaches the right audience, and connects with the intended person at the right time.

The company calls it ‘Growth as a Service’.

Client implementation is nearly effortless, since the solution is completely managed by the Electronic Servitor Publication Network team. This business model allows clients to focus on their brands, core product offerings, and content creation, while the company manages the technology and outcome.

The company is headquartered in Minneapolis, Minnesota.


Electronic Servitor Publication Network’s Digital Engagement Engine™ utilizes a combination of automation, unique data management, and a modern workflow built on a microservices architecture to achieve greater reach and lift. Using sophisticated data analysis and smart technology, the Digital Engagement Engine™ provides companies with the ability to maintain complete control of their content while creating meaningful relationships with new customers and revenue streams.

The Digital Engagement Engine™ isn’t just another marketing or technology tool; it’s a way to develop real connections with target markets.

Market Outlook

According to a report by, an award-winning market research firm, the global customer engagement solutions market was estimated at $19.3 billion in 2022 and is forecast to grow to $32.2 billion by 2027, achieving a CAGR of 10.8% during the forecast period.

The report notes that these engagement solutions are vital to companies seeking to widen their customer bases, reduce customer churn rates and increase customer retention. These perceived benefits of customer engagement solutions are likely to drive their growing adoption around the globe during the forecast period, according to the report.

Management Team

Peter Hager is President and CEO of Electronic Servitor. He joined the company from Pointward Inc., a medtech customer engagement agency that provided solutions to drive market entry, growth, and commercialization for Fortune 500 health care brands and medtech startups. He has founded and managed multiple technology, professional services and medtech organizations throughout his career. Mr. Hager holds a bachelor’s degree from Macalester College in St. Paul, Minnesota, with concentrations in economics and psychology.

Jim Kellogg is CFO of Electronic Servitor. He has served as the principal of J. Kellogg & Company Inc., a business and tax consultant, since 2005. He has provided legal support to clients’ business valuations, business interruption and divorce property valuations. He has worked as a professional tax adviser since 1983. Mr. Kellogg obtained his JD with emphasis on taxation from Western State University College of Law and was certified as a financial planner by the College for Financial Planning in 1990.

Thomas (Denny) Spruce, RPh, is COO of Electronic Servitor. He oversees company infrastructure, regulatory reporting, and strategic partner relationships, among other roles and responsibilities. He joined the company in March 2022 and, since that time, has implemented foundational support processes, developed contractual relationships with service providers, managed financial and regulatory reporting and overseen contract development and management with the legal team. Mr. Spruce obtained a BS in Pharmacy from the University of Arkansas.

Electronic Servitor Publication Network Inc. (XESP), closed Thursday's trading session at $0.07, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.03/$0.16.

Recent News

RJD Green Inc. (OTC: RJDG)

The QualityStocks Daily Newsletter would like to spotlight RJD Green Inc. (OTC: RJDG) .

RJDG acquires, manages, and grows assets in three stable sectors: healthcare billing and payment technology, specialty construction, and environmental services

Assets include ioSoft Inc., Silex Holdings Inc., and Earthlinc Environmental Solutions

RJDG's management team leverages decades of operational, management, and financial expertise to restructure, manage, and position assets for long-term returns

Diversification is one of the keys to investment success in volatile markets. With that principle in focus, the management team at RJD Green (OTC: RJDG), a holding company, is currently building wealth and generating long-term returns in several resilient markets: healthcare billing and payment technology, specialty construction, and environmental services.

RJD Green Inc. (OTC: RJDG) is a holding company focused on managing portfolio assets while actively exploring potential acquisitions and opportunities in diversified industries. The company currently operates in three divisions: RJD Green Healthcare Division, Earthlinc Environmental Solutions and Silex Holdings Inc.

The company’s corporate management team has a history of success in both public and private arenas, with diverse enterprise experience that includes RJD Green’s three current market sectors of focus. Corporate overhead is maintained at minimal operating cost, with each officer and team member maintaining daily management responsibility for specific operating divisions and entities.

Each acquisition and asset is operated as a separate profit center, with the recognition that, in small business operations, proficiency and frugal budgeting are required to maximize profitability. The RJD Green team excels in working collaboratively with the company’s business partners, creating common efforts for reaching mutual reward from its relationships.

The company is headquartered in Tulsa, Oklahoma.

Business Divisions

RJD Green Healthcare Division

Through this division, the company has developed a business model that utilizes the healthcare industry experience and extensive industry relationships of its management team. RJD Green’s leadership has long-term relationships with many key providers within the service sectors of the healthcare industry.

The first RJD Green Healthcare Division services acquisition was IoSoft Inc., a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers. The IoSoft team has years of experience and relationships within the more than a million providers in the healthcare market.

Earthlinc Environmental Solutions

This division was formed to promote green applied technologies and offer environmental services in North America. Its focus is on performance-driven solutions for environmental-based issues.

The first acquisition, Animal Waste Management, is a patented technology that is fully developed and entering the market for waste processing on commercial chicken and hog farms. Development was supported by the University of Arkansas and the Missouri Department of Natural Resources.

The acquired technology controls the liquid, solid and gas waste generated, creating an odorless, clean, bacteria-free by-product that can be used for animal feed filler, while allowing the water to be reused as ground water on the farm.

Silex Holdings Inc.

This division was formed for the purpose of acquiring and managing high growth assets and business enterprises. Its operations are focused on acquisitions in specialty industrial contracting, building material products and construction services.

Acquisitions are modeled to offer immediate growth, such as a unique geographical or proprietary market niche or other differentiating quality, and are synergistic in corporate management and administration, as well as sales and marketing.

The company’s first acquisition through this division, Silex Interiors, is a manufacturer, distributor and installer of countertops, cabinets and related kitchen and bath products. Silex is modeled for expansion into major markets nationally through internal expansion, acquisition and franchising.

Market Opportunity

According to a report from, the global healthcare services market is expected to grow from $6.8 billion in 2021 to $10.4 billion in 2026 at a CAGR of 8.6%. The report attributed the forecast growth primarily to healthcare companies restructuring their operations as a result of lasting challenges presented by the COVID-19 pandemic.

Research firm Verdantix reported the environmental services market was worth an estimated $35.2 billion in 2022 and is expected to reach a value of $50.6 billion by 2029, marking a CAGR of 6.3% for the forecast period. Verdantix identified factors driving growth to include changing environmental compliance regulations, rising demand for infrastructure projects and increased ESG reporting scrutiny.

In 2021, Icon Market Research estimated the global specialty trade contractors market at $3.9 billion, forecasting that it will reach $5.7 billion by 2028 at an expected CAGR of 9.2% through the identified period.

Management Team

Ron Brewer is CEO of RJD Green. He has served as a corporate officer in both public and private companies, including as president of Mid-Continent Companies. He has experience in all three industries represented by the company’s divisions. He has provided management and guidance to five environmental services and technology companies, as well as guiding business development services in healthcare for hospitals, practice assistance and various service providers in the sector. He has also developed three separate companies in the same construction products sector.

Jerry Niblett is COO at RJD Green. He has over 19 years of management success in oil and gas operations at both corporate and small-cap enterprises. His corporate employment history includes Dominion Energy, Texaco, Shell and Sunoco Pipeline LP. He has worked in multiple energy sectors, including petro-chemical refining, natural gas compression, crude oil pipeline and storage, oil and gas exploration, and oil and gas products and services business development. He holds a bachelor’s degree in Total Quality Management, graduating with honors.

John Rabbitt is CFO at RJD Green. He has worked at Fortune 500 firms including Pillsbury, PepsiCo and CPA firm Ernst and Ernst. He played a key role in the growth of MEI Corp. from $20 million annual revenue to $850 million annually in nine years, at which time it was acquired by PepsiCo. He has a proven track record in both fast-growth and turnaround environments, serving in CEO/COO and CFO positions for firms ranging from $5 million to $300 million annual revenue. His education includes degrees in accounting and business from Drake University and PepsiCo’s Management Institute.

RJD Green Inc. (OTC: RJDG), closed Thursday's trading session at $0.0049, even for the day, on 100,000 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0041/$0.01315.

Recent News

GolfLync Inc.

The QualityStocks Daily Newsletter would like to spotlight GolfLync Inc.

GolfLync, seen as one of the hottest and fastest growing new golf apps in social media, is pleased to announce a partnership with golfing sensation Eliezer Paul-Gindiri, nicknamed "Snappy Gilmore," whose distinctive single-handed golf swing stunned the golfing world in 2021. GolfLync's many features, including its trademarked Virtual Golf Clubs(TM) ("VGC"), private feeds, group chats, and personalized golf experiences, set it apart as the go-to social network for golfers of all levels. As Snappy Gilmore stated "Finding players is easy on GolfLync. Having my own Virtual Club allowing my followers access is great." #snappygilmore, whose TikTok clip went viral in 2021, has amassed more than 2.7 million followers, 89.2 million Likes, along with a legion of fans who can't help but try the unique swing for themselves. Snappy is a Nigerian-American amateur golfer whose focus on health and wellness, combined with solid entertainment vibes, has generated ongoing buzz with the PGA Tour, PGA Tour of America, and various charitable causes. In a July 10th 2023, article, Sports Illustrated named Snappy Gilmore as one of "The Top Ten Social Media Stars in Sports."

GolfLync Inc. matches golfers looking for a game through the company’s smartphone app, GolfLync. The company bills GolfLync as “the social network for golfers,” matching golf games and players similar to the way a dating app matches those looking for romance.

The app allows like-minded golfers to connect for a game simply by logging in. GolfLync helps golfers who are looking to grow their golf network find other players with similar interests and on course preferences. Whether you have recently moved to a new area and are looking for new golfing buddies, travel frequently and would like to play a round of golf while on the road, or just want to meet new golfers in your area, GolfLync is your answer. Spouses who enjoy golfing together can find other golfing couples to tee it up with. For a regular group that finds itself unexpectedly down a player, GolfLync can help find that last-minute addition to complete the foursome.

The company is based in Scottsdale, Arizona.

GolfLync App

GolfLync was created for golfers of all skill levels and preferences to connect with compatible players of similar skill. Golfers can find a tee time through GolfLync, join existing tee times and create new leagues. The app allows golfers to meet fellow players before committing to spend four hours on the course with them. GolfLync allows users to find new golf friends based on their preferences, such as walking or riding a cart, listening to music, friendly wagering, imbibing a favorite beverage at the 19th Hole and more. GolfLync is available for both Android and iOS as a free download.

Download on Apple App Store   Get it on Google Play

Market Opportunity

According to a report by Statista, a leading provider of market and consumer data, in 2022, the number of people participating in golf in the United States reached 25.6 million, with 15.5 million additional players participating in off-course activities like driving ranges. In 2020, over 502 million rounds of golf were played in the U.S. alone. The game, traditionally dominated by male players, is changing, with increased interest from women golfers driven by social media influencers around the game.

Lumen Sports puts the total number of golf courses in the U.S. at more than 16,700. According to Lumen, about 75% of those are public courses open to all golfers, with the rest considered private golf clubs that require a membership.


Management Team

Noah DiPasquale is a co-founder and CEO of GolfLync Inc., leading the marketing and operations of the platform. He is also the founder and CEO of Epic Golf Club, a premier national membership and private golf society which partners with hundreds of top tier private golf clubs allowing Epic members access to their courses and recently founded the Epic Foundation, a Scottsdale-based 501c3. He holds a B.S. in Business Administration, Management and Operations from the W.A. Franke College of Business at Northern Arizona University and an MBA in Marketing from the University of Phoenix.

Michael Quiel is a co-founder of GolfLync Inc. and the President of the organization. He leads the application development and research teams. Michael understands how to build successful companies. His deep knowledge of investment banking, finance and building successful business partnerships is unparalleled. He’s an expert at capital formation and growth hacking companies. He has raised over $250 million in capital and taken multiple companies public.

Recent News


Longeveron Inc. (NASDAQ: LGVN)

The QualityStocks Daily Newsletter would like to spotlight Longeveron Inc. (NASDAQ: LGVN) .

Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome ("HLHS"), Alzheimer's disease and Aging-Related Frailty, has released top-line results for its phase 2a trial of its investigational product Lomecel-B(TM). The study evaluated Lomecel-B for the treatment of mild Alzheimer's disease. According to the report, the primary endpoint of safety was met across all study groups; in addition, the secondary endpoint of change from baseline to week 39 in Composite Alzheimer's Disease Score ("CADS") also demonstrated positive results. The report also noted that other doses demonstrated numerical slowing/prevention of disease worsening relative to placebo.

"We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B in the treatment of Alzheimer's disease and provide a robust foundation for additional clinical trials in this and other indications," said Longeveron CEO Wa'el Hashad in the press release. "We look forward to announcing additional biomarker data from this trial, anticipated to be later this month, which may further characterize the clinical effects of Lomecel-B in this study population. With our phase 2 ELPIS II trial in HLHS moving toward anticipated completion in 2024, and our phase 2 program in Aging-Related Frailty progressing in Japan as well, we look forward to meaningful milestones in the near term and to fully realizing the therapeutic potential of Lomecel-B."

To view the full press release, visit

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The Company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging, with function and ability to perform activities of daily living.

Longeveron is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.

The Company’s philosophy revolves around the idea that regenerative medicine may hold the potential to improve certain rare medical conditions and contribute to healthy aging. While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging.

Longeveron’s lead investigational product is Lomecel-B™, an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors. As humans age, they experience a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation, and other issues. Clinical data has suggested that Lomecel-B™ may address these conditions through multiple mechanisms of action (MOA) that simultaneously target key aging-related processes.

The Company is headquartered in Miami, Florida.


Lomecel-B™ is being evaluated in multiple clinical trials for aging-related chronic diseases and other life-threatening conditions under U.S. FDA-approved Investigational New Drug applications. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

The drug is made from special living cells called Medicinal Signaling Cells (MSCs) that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Once the MSCs have been isolated from the fresh bone marrow through a careful selection process, the cells are culture-expanded (allowed to replicate under controlled laboratory conditions) into the billions using specialized techniques and processes. After a specific number of expansion cycles, called “passages,” the cells are harvested, separated into specific doses (e.g., 50 million cells), and cryopreserved until future use.

These cells have been shown to have characteristics that allow them to be transplanted from a donor to host without triggering a harmful immune response in the recipient, and they can be administered on an outpatient basis in as little as 40 minutes after thawing. Because of these characteristics, Lomecel-B™ is considered an “off-the-shelf” product.

In some trials, such as for Alzheimer’s disease and Aging-related Frailty, Lomecel-B™ is administered via peripheral intravenous infusion, while, in the Company’s HLHS trial, Lomecel-B™ is administered via direct injection into the heart tissue.

Market Opportunity

Longeveron estimates the potential market size for Lomecel-B™ in the treatment of HLHS to be up to $1 billion annually, globally.

U.S. patients suffering from Aging-related Frailty are estimated using U.S. Census Bureau statistics to be approximately 8.1 million. That population potentially represents a market for Lomecel-B™ of between $4 billion and $8 billion globally per year, according to Company estimates.

Additionally, the Alzheimer’s Association puts the number of Americans with that disease at 5.1 million, highlighting another potentially addressable market for Lomecel-B™, that’s worth $5 billion to $10 billion annually.

Management Team

Wa’el Hashad is CEO of Longeveron. He has more than 35 years of experience in the pharmaceutical and biotech industries. He has launched several successful brands in the U.S. and worldwide markets. Prior to joining Longeveron, he was president and CEO of Avanir Pharmaceuticals. Before Avanir, he was the chief commercial officer of Seres Therapeutics. He also has held senior leadership positions at Amgen, Boehringer Ingelheim, and Eli Lilly and Company. He holds a bachelor’s degree in pharmacy from Cairo University and an MBA from the University of Akron.

Joshua M. Hare, M.D., FACC, FAHA, is Co-Founder, Chief Science Officer and Chairman of Longeveron. He is a double board-certified cardiologist and is the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. He is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine.

Lisa Locklear is CFO at Longeveron. She previously served as the senior vice president and CFO for Avanir Pharmaceuticals. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company, and Price Waterhouse, with assignments in Paris and London. She holds a bachelor’s degree in plant science from the University of California, Davis, and an MBA from the University of California, Irvine. She is a licensed CPA (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.

Dr. Nataliya Agafonova, M.D., is the Chief Medical Officer at Longeveron. She previously served as clinical development lead, senior medical director, and product development chair at Otsuka Pharmaceuticals. Before that, she was the clinical development lead and senior medical director at Bristol-Myers Squibb. She previously held senior leadership positions at Ardea Bioscience, Biogen, Amgen, and Genzyme Corporation. She earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306

Date prepared: August 31, 2023

Longeveron Inc. (NASDAQ: LGVN), closed Thursday's trading session at $2.09, off by 16.7331%, on 10,153,523 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.88/$4.5793.

Recent News

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

The QualityStocks Daily Newsletter would like to spotlight Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

Researchers have observed coronary microvascular dysfunction in a good number of patients with psoriasis. This is despite the fact that most of them hadn't presented with any symptoms of cardiovascular illness. For their study, the researchers recruited 503 individuals who had been diagnosed with psoriasis but had not been diagnosed with cardiovascular disease. Prior research has demonstrated that individuals with severe psoriasis have heightened cardiovascular mortality and morbidity. Despite this, there's been limited studies on the mechanisms underlying the heightened risk. The researchers were focused on learning more about the link between psoriasis and heart disease, centering on coronary blood flow. They examined the coronary microvascular system and looked at the extent to which small blood vessels could expand to allow for the blood to flow without interruptions. This is referred to as coronary reserve flow. Given the additional health risks that patients diagnosed with psoriasis face, such as heightened risk for heart disease, the innovative nanosized antibody therapies that companies such as Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are working on could be a lifesaver since they could keep psoriasis in check or even reverse it so that patients don't get to a level of developing secondary complications linked to their psoriasis diagnosis.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, Scinai is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. Scinai is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, Scinai has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, Scinai signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. Scinai anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of Scinai’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

Scinai has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, Scinai will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. Scinai anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

CDMO Services

While NanoAb pipeline development is Scinai’s core focus, the company also offers its cGMP manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for contract development and manufacturing organization (CDMO) services. This offering is designed to keep the Scinai team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb pipeline development.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future Scinai drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is Scinai’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at Scinai. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at Scinai. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining Scinai, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at Scinai. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to Scinai through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), closed Thursday's trading session at $0.7, off by 6.7909%, on 21,750 volume. The average volume for the last 3 months is 38,695 and the stock's 52-week low/high is $0.70/$11.49.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.


The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Thursday's trading session at $0.678, up 0.14771%, on 40,451 volume. The average volume for the last 3 months is 46,025 and the stock's 52-week low/high is $0.6308/$8.76.

Recent News

GeoSolar Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight GeoSolar Technologies Inc.

GeoSolar Technologies Inc. (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home® system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy.

GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (HERS) in the industry.

GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular.

GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (SEC) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock.


The Decarbonization Movement

Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions.

U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models.

GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate.


The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system.
Key benefits of the GSP system include:

  • Making a real planet-changing difference in reducing air pollution
  • Eliminating or significantly reducing homeowners’ future utility bills
  • Enjoying lifetime energy independence and protection from price escalation and energy shortages
  • Eliminating greenhouse gas emissions from operation of home and daily life
  • Increasing home value
  • An integrated design for seamless operation of renewable energy systems
  • Maintaining a significantly healthier living environment
  • Leveraging existing renewable energy tax credits and electrification incentives
  • Creating stable jobs capable of supporting families in the decarbonized future

Click here to learn more about how GeoSolarPlus works.

Management Team

The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes.

Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company.

Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project.

Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens.

Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia.

Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois.

* Must be over 18, certain states are not currently available and will be added soon.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.